These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


216 related items for PubMed ID: 28891941

  • 21. Analogue-based design, synthesis and docking of non-steroidal anti-inflammatory agents. Part 2: methyl sulfanyl/methyl sulfonyl substituted 2,3-diaryl-2,3-dihydro-1H-quinazolin-4-ones.
    Manivannan E, Chaturvedi SC.
    Bioorg Med Chem; 2012 Dec 15; 20(24):7119-27. PubMed ID: 23146282
    [Abstract] [Full Text] [Related]

  • 22. Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones.
    Abdel-Aziz AA, Abou-Zeid LA, ElTahir KEH, Ayyad RR, El-Sayed MA, El-Azab AS.
    Eur J Med Chem; 2016 Oct 04; 121():410-421. PubMed ID: 27318118
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Benzodioxole-Pyrazole Hybrids as Anti-Inflammatory and Analgesic Agents with COX-1,2/5-LOX Inhibition and Antioxidant Potential.
    Abd El Razik HA, Badr MH, Atta AH, Mouneir SM, Abu-Serie MM.
    Arch Pharm (Weinheim); 2017 May 04; 350(5):. PubMed ID: 28418202
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: Molecular docking studies.
    Abdel-Aziz AA, El-Azab AS, Abou-Zeid LA, ElTahir KE, Abdel-Aziz NI, Ayyad RR, Al-Obaid AM.
    Eur J Med Chem; 2016 Jun 10; 115():121-31. PubMed ID: 26999325
    [Abstract] [Full Text] [Related]

  • 29. Molecular docking, synthesis and biological screening of mefenamic acid derivatives as anti-inflammatory agents.
    Savjani JK, Mulamkattil S, Variya B, Patel S.
    Eur J Pharmacol; 2017 Apr 15; 801():28-34. PubMed ID: 28259712
    [Abstract] [Full Text] [Related]

  • 30. Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition.
    Limongelli V, Bonomi M, Marinelli L, Gervasio FL, Cavalli A, Novellino E, Parrinello M.
    Proc Natl Acad Sci U S A; 2010 Mar 23; 107(12):5411-6. PubMed ID: 20215464
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and molecular docking of new imidazoquinazolinones as analgesic agents and selective COX-2 inhibitors.
    Hassanein HH, Georgey HH, Fouad MA, El Kerdawy AM, Said MF.
    Future Med Chem; 2017 Apr 23; 9(6):553-578. PubMed ID: 28394629
    [Abstract] [Full Text] [Related]

  • 32. Molecular docking-guided synthesis of NSAID-glucosamine bioconjugates and their evaluation as COX-1/COX-2 inhibitors with potentially reduced gastric toxicity.
    Jones Lipinski RA, Thillier Y, Morisseau C, Sebastiano CS, Smith BC, Hall CD, Katritzky AR.
    Chem Biol Drug Des; 2021 Jul 23; 98(1):102-113. PubMed ID: 33955172
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Synthesis and biological evaluation of linear phenylethynylbenzenesulfonamide regioisomers as cyclooxygenase-1/-2 (COX-1/-2) inhibitors.
    Anana R, Rao PN, Chen QH, Knaus EE.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5259-65. PubMed ID: 16635574
    [Abstract] [Full Text] [Related]

  • 35. Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study.
    Bouaziz-Terrachet S, Toumi-Maouche A, Maouche B, Taïri-Kellou S.
    J Mol Model; 2010 Dec 01; 16(12):1919-29. PubMed ID: 20237816
    [Abstract] [Full Text] [Related]

  • 36. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
    Vannini F, Chattopadhyay M, Kodela R, Rao PPN, Kashfi K.
    Redox Biol; 2015 Dec 01; 6():318-325. PubMed ID: 26319435
    [Abstract] [Full Text] [Related]

  • 37. Novel 4-methylsulfonylphenyl derivatives as NSAIDS with preferential COX-2 inhibition.
    Amin NH, Mohammed AA, Abdellatif KR.
    Future Med Chem; 2018 Jan 01; 10(1):53-70. PubMed ID: 29235887
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.
    Kalgutkar AS, Kozak KR, Crews BC, Hochgesang GP, Marnett LJ.
    J Med Chem; 1998 Nov 19; 41(24):4800-18. PubMed ID: 9822550
    [Abstract] [Full Text] [Related]

  • 40. Novel 1,3,4-oxadiazole/oxime hybrids: Synthesis, docking studies and investigation of anti-inflammatory, ulcerogenic liability and analgesic activities.
    Abd-Ellah HS, Abdel-Aziz M, Shoman ME, Beshr EA, Kaoud TS, Ahmed AF.
    Bioorg Chem; 2016 Dec 19; 69():48-63. PubMed ID: 27669120
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 11.